Vitrectomy drug alternative continues to impress

Article

The Phase IIb trial assessing the safety and efficacy of microplasmin in patients, showed complete resolution of vitreomacular traction or macular hole without need for vitrectomy surgery, according to a statement from the trial sponsor, ThromboGenics NV.

The Phase IIb trial assessing the safety and efficacy of microplasmin in patients, showed complete resolution of vitreomacular traction or macular hole without need for vitrectomy surgery, according to a statement from the trial sponsor, ThromboGenics NV.

Dr Kirk Packo, Professor and Chairman at the Department of Ophthalmology, Rush University Medical Center in Chicago, US presented the six-month results of the randomized, double-masked, multicentre, dose-evaluation study at the meeting of the American Academy of Ophthalmology (AAO).

The results, consistent with the one-month follow-up data presented at the World Ophthalmology Congress in Hong Kong, demonstrated that a 125µg intravitreal dose of microplasmin treated the condition successfully, so that the need for vitrectomy was bypassed, in approximately one third of cases. Those patients who had achieved disease resolution at one month maintained this improvement at six months. At this time point, visual acuity in patients treated successfully with microplasmin was equal to that of patients who had undergone vitrectomy.

The Phase III trial programme, assessing microplasmin as a treatment for vitreomacular adhesion, is now being finalized. The trial will begin early next year.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.